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Abstract
With an infection rate of 60–90%, the human cytomegalovirus (HCMV) is very common among adults but normally causes 
no symptoms. When T cell-mediated immunity is compromised, HCMV reactivation can lead to increased morbidity and 
mortality. HCMV antigens are processed and presented as peptides on the cell surface via HLA I complexes to the T cell 
receptor (TCR) of T cells. The generation of antibodies against HCMV peptides presented on HLA complexes (TCR-like 
antibodies) has been described, but is without therapeutic applications to date due to the polygenic and polymorphic nature of 
HLA genes. We set out to obtain antibodies specific for HLA/HCMV-peptides, covering the majority of HLA alleles present 
in European populations. Using phage display technology, we selected 10 Fabs, able to bind to HCMV-peptides presented 
in the 6 different HLA class I alleles A*0101, A*0201, A*2402, B*0702, B*0801 and B*3501. We demonstrate specific 
binding of all selected Fabs to HLA-typed lymphoblastoid cell lines (EBV-transformed B cells) and lymphocytes loaded with 
HCMV-peptides. After infection with HCMV, 4/10 tetramerized Fabs restricted to the alleles HLA-A*0101, HLA-A*0201 
and HLA-B*0702 showed binding to infected primary fibroblasts. When linked to the pseudomonas exotoxin A, these Fab 
antibodies induce highly specific cytotoxicity in HLA matched cell lines loaded with HCMV peptides. TCR-like antibody 
repertoires therefore represent a promising new treatment modality for viral infections and may also have applications in 
the treatment of cancers.
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Introduction
HCMV is a double-stranded DNA virus and member of the 
Herpesviridae family. Like all herpesviruses, HCMV per-
sists after acute infection and establishes latent infection 
in a non- or slowly replicating form. Host cells for latent 
infection can be neutrophils, T lymphocytes, endothelial 
cells, renal epithelial cells or salivary glands [2]. Infection 
with HCMV is very common among adults (60–90%) and 
primary infection often does not cause any symptoms. In 
rare cases primary infection can cause HCMV mononu-
cleosis with fever, lymphadenopathy and relative lympho-
cytosis. Usually, HCMV infection resolves quickly and 
is controlled by CD8+, CMV-specific T cells [2]. After 
allogeneic hematopoietic stem cell transplantation (HSCT) 
or solid organ transplantation, T cell-mediated immunity is 
often suppressed and HCMV reactivation can significantly 
contribute to morbidity and mortality after transplantation 
[3, 4]. HCMV is one of the most common opportunistic 
pathogens detected after HSCT or solid organ transplanta-
tion and can cause severe pneumonia, hepatitis, encephali-
tis, colitis or ulcers of the gastrointestinal tract [3, 4]. Not 
only patients undergoing transplantation but also patients 
with HIV-induced immunodeficiency suffer from HCMV-
related diseases like retinitis and polyradiculopathy [5, 6].
Despite serious side effects and the selection of drug-
resistant strains, ganciclovir and valganciclovir remain 
the mainstay in the management of HCMV-associated 
disease after allogeneic stem cell transplantation and in 
solid organ recipients [7]. For patients after heart and lung 
transplantation a universal prophylaxis with (val-) gan-
ciclovir is recommended. For the remaining solid organ 
transplantations, a preemptive therapeutic strategy guided 
by detection and surveillance of HCMV DNA or antigen is 
the standard procedure [3, 8]. The first-line treatment for 
HCMV disease is usually intravenous (i.v.) ganciclovir or 
oral valganciclovir. In life threatening cases i. v. ganciclo-
vir in combination with HCMV-specific immunoglobulin 
should be administered. Second-line therapeutic options 
are foscarnet and cidofovir [3, 4]. Recently, with the FDA 
approval of the HCMV terminase inhibitor letermovir, a 
new class of HCMV drugs for prophylaxis and treatment 
has become available [9]. But even with letermovir proph-
ylaxis, 38% of patients after allogeneic HSCT developed 
HCMV infection, illustrating the need for new treatment 
options of HCMV disease. Another treatment option for 
HCMV infection after allogeneic HSCT is the transfer 
of donor-derived HCMV-specific T cells, but this option 
remains labor-intensive hampering its routine application 
[10].
The proteome of nucleated cells is displayed perma-
nently on the cell surface by degradation of intracellular 
proteins and presentation of the peptide fragments in class 
I major histocompatibility complexes [MHC I; human leu-
kocyte antigen I (HLA I) in humans]. Displaying tumor- 
or virus-derived antigenic peptides, malignant or infected 
cells can be distinguished by T cells from their healthy 
counterparts [11]. HCMV infection is controlled by CD8+ 
T cells that recognize HCMV peptides presented on HLA 
class I complexes of infected cells and mount potent 
immune responses [12]. The humoral immune response 
plays only a minor role in controlling latent HCMV infec-
tion. Long term immunity against HCMV mostly depends 
on T cells, despite the fact that several antibodies against 
different HCMV antigens are detectable after primary 
infection [13].
The identification and generation of antibodies directed 
against viral peptides presented on HLA I complexes has 
been described previously. However, so far there are no 
therapeutic or diagnostic applications of such antibodies, 
generally referred to as T cell receptor (TCR) like antibod-
ies [14, 15]. The biggest handicap of TCR-like antibodies 
is their restriction to certain HLA alleles and complexes. 
To make use of TCR-like antibodies in the diagnosis and 
treatment of viral infections, a whole repertoire of antibod-
ies covering the HLA variety of a given population would 
be necessary. Since different peptides can be presented by 
the same HLA I molecule and an individual expresses a 
unique set of HLA I alleles, many HLA/HCMV-peptide 
combinations as targets for TCR-like antibodies are con-
ceivable. The following HLA alleles cover approximately 
80% of the German population: HLA-A*0101, HLA-
A*0201, HLA-A*2402, HLA-B*0702, HLA-B*0801, 
HLA-B*3501. Although their frequencies vary, these 
HLA I alleles are also very common in other European 
populations. The most immunodominant HCMV-peptides 
presented by these HLA molecules are derived from the 
HCMV antigens pp65 and IE-1. Accordingly, they are the 
most targeted antigens of HCMV by CD8+ T cells [16, 
17]. Phage display technology represents a very potent 
approach in selecting antigen-specific antibodies and can 
also be used to identify TCR-like antibodies [14, 18].
We set out to obtain antibodies specific for HLA I/
HCMV-peptide complexes covering the majority of HLA 
alleles present in European populations using phage 
display. Selected Fab antibodies were tested and char-
acterized for specific binding to HLA I/HCMV-peptide 
complexes by ELISA and flow cytometric analysis using 
different types of target cells. To show the therapeutic 
potential of our approach, we incorporated the identified 
HCMV-specific TCR-like Fabs with pseudomonas exo-
toxin A (ETA) into immunotoxins to treat HLA matched 
and HCMV-peptide-loaded cell lines.
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Materials and methods
Selection of HLA alleles and HCMV‑peptides 
for phage display
To identify the most common HLA class I alleles, we used 
the online, free accessible “The Allele Frequency Net Data-
base.” For calculation of HLA frequency and distribution, 
the “Germany pop 8” dataset [19] was used. A comprehen-
sive literature search using the online US national library of 
medicine of the national institutes of health (Pubmed) was 
performed to identify HCMV-epitopes that elicit a T cell 
response [20].
Generation of HLA I/peptide complexes
HLA I/peptide monomers were produced as previously 
described [21]. Peptides were bought from GeneCust® 
(GeneCust, 5690 Ellange, Luxembourg). Plasmids for β2 
microglobulin and the HLA A*0201 heavy chain were pro-
vided by the Ludwig Institute of Cancer Research (Lausanne 
Branch, University of Lausanne, Epalinges, Switzerland). 
Plasmids for A*0101, A*2402 and B*0702 heavy chains 
were kindly provided by the NIH Tetramer Facility. B*0801 
and B*3501 heavy chains were cloned at our laboratory. 
Heavy chains were biotinylated in vivo using the biotinyla-
tion sequence AviTag and an IPTG inducible pASYC vector 
encoding the BirA enzyme [22].
Selection of HLA‑restricted and HCMV‑specific Fabs
The phagemid library used in this study consists of a large, 
nonimmune human Fab repertoire containing 3.7 × 1010 
different antibody fragments [23]. 1.8 × 1012 phages were 
pre-incubated in 2% nonfat dry milk, PBS and streptavidin-
coated magnetic beads (Hyglos GmbH, 82347 Bernried, 
Germany). Phages were incubated for 1 h with biotinylated 
HLA I/peptide complexes at decreasing concentrations (300, 
100, 20 and 5 nM). Streptavidin beads were added for 15 min 
followed by 12 cycles of washing. Bound phages were eluted 
with 100 mM triethylamine. Sequences of selected antibody 
clones were evaluated using the “ImMunoGeneTics informa-
tion system®” and “The National Center for Biotechnology 
Information” online tools V-QUEST and BLAST [24–26].
Expression and biotinylation of Fabs and Fab‑ETA′ 
immunotoxins
Recombinant soluble Fab antibodies were expressed in TG1 
E. coli bacteria and purified by immobilized metal affin-
ity chromatography (IMAC) using Talon beads (Takara Bio 
USA, Inc., Mountain View, CA, USA) as described previ-
ously [27]. In vivo biotinylation was performed as described 
previously [28]. To generate Fab-ETA′ immunotoxins, the 
biotinylation sequence AviTag was replaced by the sequence 
of a truncated version of the pseudomonas exotoxin A 
(ETA′). For better intracellular transport and efficacy, the 
5 C-terminal amino acids of ETA′ were exchanged for the 
KDEL motif by PCR [29]. Expression of FAB-ETA′ immu-
notoxins was performed in E. coli strain TG1.
Cell culture
Melanoma cell lines Me 260, Me 275 and SK-mel-23, the 
squamous cell carcinoma cell line A-431 and the human 
lung fibroblast cell line MRC-5 were used in this study. 
All cell lines were cultured in RPMI 1640 medium supple-
mented with 10% fetal calf serum, 100 units/ml penicillin/
streptomycin and 2 mM/ml glutamine. LCLs were gener-
ated by in vitro infection of PBMCs with EBV. Peripheral 
blood was donated from HLA-typed healthy individuals. All 
cell lines and LCLs were cultured in RPMI 1640 medium 
supplemented with 10% fetal calf serum, 100 units/ml peni-
cillin/streptomycin and 2 mM/ml glutamine. To generate 
primary skin fibroblast cell cultures, skin punch biopsies of 
HLA-typed donors were obtained and treated by standard 
procedure [30, 31].
ELISA of phages and Fab antibodies
ELISAs were performed between indirectly coated HLA I/
peptide complexes and phage clones or Fab antibodies [32]. 
Plate-bound streptavidin (5 µg/ml) was incubated with bioti-
nylated HLA I/peptide complexes at 4 µg/ml. To confirm 
correct folding of HLA I/peptide complexes, we used the 
conformation-specific monoclonal antibody Tü155 (kindly 
provided by A. Ziegler, Berlin, Germany). Fab antibod-
ies were incubated with indirectly coated HLA I/peptide 
complexes at a concentration of 10 µg/ml for 1 h at room 
temperature. Fab binding was confirmed using the murine 
anti-myc antibody 9E10 (Roche, Mannheim, Germany) and 
a horseradish peroxidase-conjugated anti-mouse IgG (Dako, 
Glostrup, Denmark). Bound phages were detected using the 
murine IgG antibody M13 (Amersham Pharmacia Biotech, 
Sweden).
Generation of Fab tetramers
Soluble Fabs were tetramerized by adding R-phycoerythrin 
(R-PE) conjugated streptavidin (ProZyme, Ballerup, Den-
mark) to biotinylated Fab monomers in a molecular ratio 
of 1:4 [33].
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Peptide loading of LCLs, lymphocytes and cell lines
LCLs, lymphocytes and cell lines were loaded with 
HCMV- and control-peptides. 5 × 105 LCLs or 100 µl 
EDTA blood were washed twice with PBS and incubated 
for 2 h at 37 °C with 20 µg/ml HCMV- or control-peptide. 
For peptide-loading of cell lines, 5 × 103 cells were washed 
twice with PBS and incubated over night with 50 µg/ml of 
either HCMV- or control-peptides.
Flow cytometry
LCLs or blood cells were incubated for 15 min with bioti-
nylated Fab antibodies (20 µg/ml for LCLs, 50 µg/ml for 
blood cells) followed by Streptavidin-conjugated R-PE 
(1:300, 15 min) from Jackson, West Grove, PA, USA. 
HCMV-infected fibroblasts were detached with trypsin 
and treated according to LCLs. Fab-tetramers were applied 
at 20 µg/ml. Fab-ETA′ constructs were detected by anti-
Pseudomonas exotoxin A polyclonal rabbit serum (Sigma, 
St. Louis, Missouri, USA, catalogue number P2318), 
1:300 diluted biotinylated anti-Rabbit IgG (DIANOVA 
GmbH, Hamburg, Germany) and streptavidin-conjugated 
R-PE (Jackson, West Grove, PA, USA). Experiments were 
performed on the BD FACS Canto. FACS Diva software 
and WinMDI 2.8 (Purdue University Cytometry Labora-
tories) were used for analysis. If possible, at least  104 cells 
were analyzed. Geometric mean fluorescence intensity 
(gMFI) values were compared between HCMV-infected 
and uninfected fibroblasts and given as mean values of all 
performed experiments.
Surface plasmon resonance experiments
Surface plasmon resonance imaging was performed with 
a BIAcore2000 (BIAcore AB, Uppsala, Sweden). Phos-
phate-buffered saline (pH 7.4) served as running buffer. 
Capture of Streptavidin (20 µg/ml in 10 mM sodium ace-
tate buffer, pH 4.2) to a CM5 sensor chip was performed 
using standard amine coupling chemistry to reach a level 
of 7000 RU. Biotinylated HLA class I/HCMV-peptide 
complexes were immobilized as ligands at target densities 
of approximately 150 RU. The purified Fabs were injected 
at concentrations of 1 µM, 0.5 µM, 0.25 µM, 0.125 µM and 
0.0625 µM with a flow rate of 30 µl/min. To establish a 
baseline, Fabs were injected on a flow cell on which only 
Streptavidin was immobilized. Association and dissocia-
tion rate constants (ka and kd) and the dissociation constant 
(KD) were determined by single cycle kinetics using the 
BIA evaluation version 4.1.1 software.
Infection of fibroblast culture with HCMV strain 
AD169
Cultures of primary fibroblasts and MRC-5 cells were 
infected at a MOI of 0.5–1.0 with the laboratory HCMV 
strain AD169, which was kindly provided by Prof. S. Smola.
Assessment of cell viability
Cells were loaded with 10–50 µg/ml HCMV- or control 
peptide at 37 °C overnight. Anti-Pseudomonas exotoxin A 
polyclonal rabbit serum (Sigma, St. Louis, Missouri, USA, 
catalogue number P2318) was used to show binding of Fab-
ETA′ immunotoxins to peptide loaded cell lines. 5 × 103 
Table 1  HLA alleles, their distribution, HCMV-derived T cell epitopes, their HLA-restriction and corresponding binding scores
HLA allele A*0101 A*0201 A*2402 B*0702 B*0801 B*3501
Allele frequency (Ger-
man reference)
15.1% 26.7% 9.5% 12.0% 9.5% 6.2%
HCMV antigen pp65 pp65 pp65 pp65 IE1 pp65
Antigen-derived peptide YSEHPTFTSQY NLVPMVATV QYDPVAALF TPRVTGGGAM ELRRKMMYM IPSINVHHY
SYFPEITHI score 29 (predicted for HLA A*01) 30 24 19 24 (predicted for 
HLA B*08)
20
Fig. 1  Specificity of selected HLA I/HCMV-peptide-specific Fabs 
as measured by ELISA. a–f show ELISA data of all identified HLA-
restricted and HCMV-peptide-specific Fab antibodies sorted by HLA 
restriction. Biotinylated HLA I complexes presenting a matching 
HCMV peptide (Table  1) or 3 control-peptides of different origins 
(Table S3) were folded and indirectly coated onto ELISA plates at a 
concentration of 4  µg/ml via streptavidin (5  µg/ml). HLA-restricted 
and HCMV-specific Fabs were applied at a concentration of 10  µg/
ml. HCMV target peptides used for HLA I complex folding are 
shown in Fig.  1 beneath the columns (abbreviated to first 3 amino 
acids) with the originating HCMV antigen. a Shows the A*0101 
restricted, HCMV-peptide-specific Fabs A6 and F3. Three Fabs (C1, 
A11, A9) could be identified, that are specific for HCMV-peptides 
presented in the A*0201 HLA allele (b). Only one Fab with speci-
ficity for HLA I/HCMV-peptides was selected for the HLA alleles 
A*2402 (C12/2 Fab in c), B*0801 (2A2 Fab in e) and B*3501 (C5 
Fab in f). The Fabs C7 and D10 show binding capacity to HCMV-
peptides but not to control peptides presented in the MHC complex of 
the B*0702 allele (d)
◂
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peptide loaded cells per well were seeded in 96-well plates 
(Nunc) and incubated with Fab-ETA′ constructs (0.1–15 µg/
ml) for 24–48 h. 10 µl of alamarBlue™ (Catalogue number 
DAL1025, from Invitrogen, Carlsbad, CA, USA) [34] were 
added into each well for a total volume of 100 µl. Data were 
collected using an Infinite® 200 PRO microplate reader 
from Tecan (Männedorf, Swiss). All experiments were 
performed at least in triplicate. Changes in viability were 
detected as reduction in fluorescence. Estimated viability of 
cell lines after treatment is given as relative viability.
Results
Identification of suitable HLA I/HCMV‑peptide 
complexes
Using the allele frequency net database [19], we identified 
the 7 most prevalent HLA I alleles in the German and most 
European populations. We found that T cell responses with 
specificity for 6 HCMV-derived peptides presented on 6/7 of 
these most prevalent HLA I complexes, have previously been 
described [35–38]. These 6 HLA I alleles (Table 1) occur in 
up to 80% of many European populations [39]. Five of six 
peptides that induce T cell responses derive from the immu-
nodominant HCMV-antigen pp65 and one peptide derives 
from IE1 (Table 1). We used these 6 HLA I/HCMV-peptide 
complexes to select and characterize TCR-like, CMV-spe-
cific antibodies by phage display.
Selection of HLA I/HCMV‑peptide‑specific Fabs
A total of 10 Fabs were obtained covering 6 HLA I alleles. 
Two different HLA I-restricted, HCMV-specific Fab clones 
could be obtained for the alleles A*0101 and B*0702, three 
different Fabs were identified for the HLA allele A*0201 
and only one HCMV-specific clone for the remaining alleles. 
Further details regarding the sequences and variable regions 
of the Fabs are given in the supplement (Tables S1 and S2).
Characterization of the HLA I/HCMV‑peptide‑specific 
Fabs
TCR‑like Fabs tested by ELISA
We used ELISAs to test for unselective binding of selected 
Fabs to corresponding HLA I complexes folded with differ-
ent control peptides (Table S3). HLA I/HCMV-peptide com-
plexes and HLA I/control-peptide complexes were coated on 
ELISA microplates. All described Fabs exclusively bound 
to their matching HLA I/HCMV-peptide complex but not 
to any control-peptide presented by the same HLA complex 
(Fig. 1).
TCR‑like Fabs on peptide‑loaded LCLs and lymphocytes
LCLs were loaded with HLA-matching HCMV-peptide or 
with control-peptides for further testing of the TCR-like 
Fab antibodies by flow cytometry. All Fabs proved to bind 
specifically to HCMV-peptide loaded LCLs expressing the 
corresponding HLA allele and did not bind to same LCLs 
loaded with control-peptides or DMSO mock-loaded LCLs 
(Fig. 2). Moreover, all Fabs showed no unspecific binding 
to LCLs with not-matching HLA alleles (data not shown).
To determine detection limits of the selected TCR-like 
Fabs we performed experiments titrating HCMV-peptides 
and Fab antibodies. LCLs were loaded with matching 
HCMV-peptides at constant concentrations of 20 µg/ml and 
stained with TCR-like Fab antibodies in decreasing con-
centrations from 20 to 0 µg/ml (Figure S1). At a concen-
tration of 20 µg/ml, all Fabs demonstrated clear binding to 
HCMV-peptide-pulsed LCLs, with some of the Fabs show-
ing binding capacity down to concentrations of below 1 µg/
ml. Reversely, the concentrations of HCMV-peptides used 
for LCL-loading were titrated from 20 to 0 µg/ml (Figure 
S2). Fab staining of HCMV-peptide-pulsed LCLs was pos-
sible down to HCMV-peptide concentrations of 2.5 µg/ml.
HCMV-specific Fab antibodies were further tested on 
HCMV-peptide-loaded native lymphocytes. HLA A*0101, 
A*0201 and B*0701 positive lymphocytes were isolated 
from the same donors LCLs were generated from. HLA 
A*2402, B*0801 and B*3501 expressing lymphocytes 
were obtained from different donors as the HLA-corre-
sponding LCLs. Staining of lymphocytes with HLA I/
HCMV-peptide-specific Fabs showed similar results as the 
LCL experiments (Figure S7). In order to exclude relevant 
Fig. 2  Binding assay of HLA I/HCMV-peptide-specific Fabs on 
LCLs. LCLs were generated by EBV infection of lymphocytes of 
HLA-typed donors. Peptide pulsing was done by incubation with 
20  µg/ml HCMV-peptide (black line) and three control peptides 
(green, blue and purple lines) for 2 h at 37 °C. HCMV-peptides used 
for LCL pulsing are listed in Table 1 and control peptides are listed 
in Table S3. For staining experiments, peptide-pulsed LCL cells were 
incubated with 20 µg/ml biotinylated HLA I/HCMV-peptide-specific 
Fab antibodies for 15 min at RT. Histograms of the staining experi-
ments are assorted from top to bottom by HLA I alleles. A*0101: 
HLA-restricted and HCMV-specific Fabs A6 and F3 were tested and 
showed specific binding to HCMV-peptide-loaded LCLs expressing 
the allele A*0101. Control peptides used were peptides 1, 2 and 3. 
A*0201: The three TCR-like Fab antibodies C1, A11 and A9 bind 
to HCMV-peptide-pulsed LCLs and not to the same LCLs pulsed 
with the control peptides 13, 12 and 10. A*2402: Binding assay of 
the HLA I/HCMV-specific Fab C12.2 (control peptides 11, 5 and 4) 
showing specific binding. B*0702: Histograms of C7 and D10 after 
incubation with HLA matched LCLs. Both Fabs interact only with 
LCLs that were pulsed with HCMV-peptide and not with same LCLs 
pulsed with the control peptides 10, 6 and 7. B*0801: 2A2 binds to 
HCMV-peptide-pulsed LCLs. As controls, the peptides 8, 6 and 
7 were used. B*3501: The Fab antibody C5 shows affinity towards 
HCMV-peptide-pulsed LCLs (control-peptides used were 10, 6 and 7)
◂
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interpatient variability, we performed staining experiments 
of peptide-loaded lymphocytes from different donors (Fig-
ure S4). For most Fabs, some difference in binding affinity 
between two lymphocyte donors was detected, but their 
general ability to bind to HCMV-peptide-loaded lympho-
cytes of matching HLA I-status was not affected and there-
fore not donor-dependent.
TCR‑like Fabs and Fab tetramers on HCMV‑infected 
fibroblasts
To evaluate the ability of the Fab antibodies to rec-
ognize naturally processed HCMV-peptides, we used 
HCMV-infected primary skin fibroblasts obtained from 
HLA I-typed volunteers. We established 11 primary skin 
fibroblast cultures (Table S4). Infection with the HCMV 
strain AD169 was confirmed by western blot analysis of 
the HCMV-antigen pp65 (data not shown). Monomeric 
Fabs showed no binding to HCMV-infected fibroblasts as 
measured by flow cytometry (data not shown). To enhance 
staining intensity, we generated Fab tetramers and assem-
bled seven HCMV specific Fab tetramers from following 
Fabs: A6, F3, C1, C12.2, C7, 2A2 and C5 (Table 2).
As shown in Fig. 3, Fab tetramers of the Fabs A6, F3, 
C1 and C7 bound to HCMV-infected, HLA-matched fibro-
blasts. Not-infected fibroblasts or HCMV-infected fibro-
blasts expressing different HLA alleles served as controls 
and could not be stained. Fab tetramer staining experi-
ments were repeated at least 4 times on different fibroblast 
cells (Figure S3). P-values of the difference in fluorescence 
intensity with and without HCMV-infection were 0.030, 
0.0001 and 0.014 for A6-, C1- and C7-tetramers, respec-
tively, demonstrating statistically significant binding of 
Fab tetramers to HCMV-infected fibroblasts. C12.2, 2A2 
and C5 (Table 2) tetramers did not bind HCMV-infected 
fibroblasts with permissive HLA alleles (Figure S8).
Determination of binding kinetics and affinity of A6, 
C1 and C7
Using surface plasmon resonance, we determined bind-
ing kinetics and affinity of the HCMV specific, TCR-like 
Fab antibodies A6, C1 and C7 to HLA I/HCMV-peptide 
complexes (Figure S9). For the Fabs A6, C1 and C7 dis-
sociation constant (KD) values of 7.6e10−9, 6.6e10−7 and 
1.9e10−6 were calculated, showing the highest affinity for 
A6. Association rate constants (ka) for A6, C1 and C7 were 
7.78e104, 4.63e104 and 1.01e104, respectively. Dissociation 
rate constants (kd) were 5.89e10−4 (A6), 2.99e10−2 (C1) and 
1.94e10−2 (C7) (Table S5).
Cytotoxic effects of HLA I/HCMV‑peptide‑specific 
immunotoxins
A6, C1 and C7 were linked to a truncated version of pseu-
domonas exotoxin A (ETA′) in order to show the therapeu-
tic potential of HCMV specific, TCR-like Fab antibodies 
(Fig. 4). A6-ETA′ showed highly specific killing of A*0101 
expressing Me 260 cells loaded with HCMV peptide. Rela-
tive viability of these cells was reduced to 40% as compared 
to Me 260 cells loaded with control peptides or HCMV-
peptide-loaded Me 275cells (A*0101-negative). C1-ETA′ 
reduced the relative viability of HCMV-peptide-loaded 
A*0201-positive SK-mel-23 cells to 50% as compared to 
controls (SK-mel-23 cells loaded with control-peptides, 
HCMV-peptide-loaded A*0201-negative Me 260 cells). 
C7-ETA′ was tested on B*0702-positive A431 cells and 
B*0702-negative Me 260 cells as control. As seen with 
the other immunotoxins, C7-ETA′ treatment resulted in 
a reduction of cell viability to 30% specifically in A431 
cells pulsed with HCMV-peptide. At C7-ETA′ concentra-
tions above 5 µg/ml, the immunotoxin showed unspecific 
Table 2  HLA I/HCMV-specific 
Fabs obtained by phage display
HLA allele A*0101 A*0201 A*2402 B*0702 B*0801 B*3501
ID Fab #1 A6 C1 C12/2 C7 2A2 C5
ID Fab #2 F3 A11 – D10 – –
ID Fab #3 – A9 – – – –
Fig. 3  Binding assays of HLA I/HCMV-peptide-specific Fab tetram-
ers to HCMV-infected fibroblasts. Tetramerized HCMV-specific 
Fab antibodies restricted to the HLA alleles A*0101, A*0201 and 
B*0702 show binding only to HCMV infected fibroblasts expressing 
the respective HLA allele and not to uninfected primary human skin 
fibroblasts (histograms on the left). All generated primary fibroblast 
cell cultures are shown in Table S4. A*0101: Both Fabs A6 and F3 
show binding capacity to the HCMV infected primary fibroblast cells 
of Fibro2. As negative controls infected as well as uninfected fibro-
blasts were incubated with the Fabs C7 and 2A2 which are HCMV-
specific but restricted to the HLA alleles B*0702 and B*0801 not 
expressed by Fibro2. A*0201: Tetramerized Fab C1 bound specifi-
cally to HCMV infected fibroblasts of Fibro5. As negative controls 
fibroblasts were incubated with the A*0101 and A*2402 restricted 
Fabs A6 and C12.2. B*0702: The C7 Fab tetramer and not the tetram-
ers of C1 and C12.2, which are HCMV specific but restricted to the 
HLA I alleles A*0201 and A*2402, bound to the HCMV infected pri-
mary skin fibroblast cell culture Fibro4. None of the Fabs bound to 
uninfected fibroblasts of Fibro4
◂
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Fig. 4  Highly specific cytotoxic effects of A1, C1 and C7 on HLA-
matched cell lines loaded with HCMV peptides. To test the therapeu-
tic potential of the identified HCMV-specific and HLA-restricted Fab 
antibodies, we generated TCR-like immunotoxins linking respective 
Fabs to a truncated version of the pseudomonas exotoxin A (ETA′). 
Cytotoxicity was assessed using alamarBlue® cell viability assays 
after 24–48 h of incubation with the generated immunotoxins at dif-
ferent concentrations ranging from 0.1 to 15  µg/ml. a A6-ETA′: As 
shown in the top diagram A6-ETA′ was highly specific in killing 
A*0101 expressing melanoma cells of the cell line Me 260 that were 
loaded with the appropriate HCMV peptide pp65/YSE (Me260/CMV). 
When loaded with DMSO alone or control peptides (Table S3), the 
viability of these cells was not affected (Me260/DMSO, Me260/Pep2, 
Me260/Pep3). Cells from a cell line expressing a different HLA allele 
than A*0101 pulsed correspondingly with HCMV (pp65/YSE)- and 
control peptides were also not affected (Me275/DMSO, Me275/
CMV, Me275/Pep2, Me275/Pep3). C1-ETA′: We tested C1-ETA′ 
on cells of the A*0201 positive cell line SK-mel-23 that were either 
mock-loaded with DMSO or matching HCMV (pp65/NLV)- and con-
trol peptides (23/DMSO, 23/CMV, 23/Pep10, 23/Pep13). As further 
controls, we used cells of the A*0201 negative cell line Me 260 that 
were mock-loaded with DMSO or pulsed with matching HCMV- 
and control peptides (Me260/DMSO, Me260/CMV, Me260/Pep10, 
Me260/Pep13). HCMV-peptide-loaded SK-mel-23 cells that were 
treated with C1-ETA′ showed reduced viability of 50% as compared 
to controls. C7-ETA′: This HCMV-specific TCR-like immunotoxin 
was tested on cells of the B*0702 expressing cell line A431 and the 
control cell line Me 260 which does not express B*0702. As seen 
with the other immunotoxins, C7-ETA′ exerted cytotoxic effects spe-
cifically on B*0702 positive cells pulsed with the respective HCMV-
peptide (pp65/TPR). All cells were either mock-loaded with DMSO 
or matching HCMV- and control peptides (A431/DMSO, A431/CMV, 
A431/Pep1, A431/Pep2, Me260/DMSO, Me260/CMV, Me260/Pep1, 
Me260/Pep2). b Photographs of Me 260, Sk-Mel 23 and A431 cells 
after treatment with Fab-ETA′ constructs (10–15 µg/ml). Images on 
the left show cells mock-loaded with DMSO. Images on the right 
show cells loaded with matching HCMV-peptides. HCMV-peptides 
and Fab-ETA′ constructs are indicated in the heading. c Flow cyto-
metric binding assays of Fab-ETA′ constructs to peptide loaded 
(50  µg/ml HCMV- or control-peptide) cell lines used for cytotoxic-
ity assays. A6, C1 and C7 ETA′ constructs (25 µg/ml) showed spe-
cific binding to HCMV-peptide loaded cell lines expressing matching 
HLA alleles, whereas HLA matching cell lines loaded with control-
peptides could not be stained. Also, cell lines of not matching HLA 
I status that were loaded with HCMV-peptides showed no binding to 
respective Fab-ETA′ constructs
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cytotoxic effects as it reduced the relative viability of the 
controls to 60–80%.
C1‑ETA′ on HCMV‑peptide‑loaded MRC‑5 cells
MRC-5 cells are HLA A*0201 expressing fibroblasts that 
can be infected with the HCMV strain AD169. After load-
ing with HCMV-peptide, C1-ETA′ shows specific binding 
to MRC-5 cells (see figure S5a). After IFNγ treatment, 
C1-ETA′ educed the relative viability of MRC-5 cells pulsed 
with 50 µg/ml HCMV-peptide to less than 40% (see fig-
ure S5 c). To determine the amount of HCMV-peptide pre-
sented on the surface of HCMV-infected MRC-5 cells, we 
performed HCMV-peptide titration experiments and found 
comparable staining intensities for MRC-5 cells loaded with 
10–20 µg/ml HCMV-peptide as for HCMV-infected MRC-5 
cells (see figure S6a and b). When incubated with MRC-5 
cells loaded with 12.5 µg/ml HCMV-peptide, C1-ETA′ was 
able to reduce MRC-5 cell viability, demonstrating its ability 
to be effective even when the target peptide is presented only 
in low concentrations (Figure S6 c).
Discussion
In situations where immunosuppression is mandatory, 
HCMV-specific TCR-like antibodies may help to overcome 
HCMV infections. The major limitation of TCR-like anti-
bodies is their restriction to a single HLA I allele [40] and 
almost all TCR-like antibodies that have been described so 
far are restricted to the HLA allele families A*02, A*24 and 
A*01 [14, 41]. To make use of TCR-like antibodies in the 
treatment of HCMV infections, a whole TCR-like antibody 
repertoire covering more HLA I alleles and their respective 
HCMV-peptides is necessary.
Here, we describe an HCMV-specific, TCR-like anti-
body repertoire which is restricted to 6 HLA alleles that are 
highly prevalent in most European populations. On LCLs 
and lymphocytes that were externally loaded with HCMV-
peptide, the selected TCR-like Fab antibodies showed spe-
cific binding. We tried to determine the detection limits of 
each selected TCR-like Fab antibody by performing titration 
experiments of the HCMV-peptide concentration used for 
LCL loading as well as of the Fab antibody concentration. 
Both varied significantly between individual TCR-like Fabs 
and the lower detection limit for HCMV-peptide-loading 
concentrations was found to be at 2.5 µg/ml.
In an experimental setting simulating natural HCMV 
infection more adequately, Fabs were tested on HCMV-
infected primary fibroblasts. Since presentation of naturally 
processed peptides resulting from infection is weaker com-
pared to peptide loading, we repeated the staining experi-
ments using tetramerized Fabs to increase their avidity. 
In doing so, we demonstrated binding to HCMV-infected 
primary fibroblasts for 4/10 of the HLA I/HCMV-peptide-
specific Fab antibodies selected in this study. Due to the 
fact that these HMCV-specific TCR-like Fab antibodies 
are restricted to the highly prevalent HLA alleles A*0101, 
A*0201 and B*0702, up to 50% of European patients 
would be eligible for treatment with respective TCR-like 
Fabs. Interestingly, not all HLA/HCMV-peptide-specific 
Fabs that tested positive on HCMV-peptide-pulsed LCLs 
and lymphocytes showed also binding to HCMV-infected 
fibroblasts. We attribute this discrepancy to immune evasion 
mechanisms of HCMV that are of no relevance after peptide 
pulsing and to the different affinities of selected TCR-like 
Fabs. The amount of HLA complexes and of HCMV-peptide 
on the cell surface of infected fibroblasts will be much lower 
after infection than after peptide-loading.
To show the therapeutic potential of the identified 
HCMV-specific, TCR-like Fab antibodies we determined 
the binding affinity and cytotoxic efficacy of A6, C1 and C7, 
which are restricted to the most prevalent HLA class I alleles 
A*0101, A*0201 and B*0702. We first used ETA′-coupled 
immunotoxins of A6, C1 and C7 on HLA-matched infected 
fibroblasts but could not detect any cytotoxic effects, which 
was attributed to a lack of internalization of HLA/peptide 
complexes by fibroblasts. Since HCMV infection of the 
alternatively used cell lines Me260, SK-mel-23 and A431 
was not possible, external HCMV-peptide loading was used 
as surrogate. While displaying different binding affinities 
to HLA I/HCMV-peptide complexes, all three immunotox-
ins conferred similar cytotoxic effects on HCMV-peptide 
loaded cell lines expressing matching HLA I alleles (Fig. 4). 
Using this experimental setup, we could show that cell lines 
expressing different HLA I alleles, simulating patients of 
different HLA status, can be targeted by a TCR-like anti-
body-immunotoxin repertoire. One major concern of thera-
peutics that are directed against viral- or tumor-derived 
peptides presented on HLA class I molecules is the low 
abundancy of such peptides presented on the cell surface. 
Peptide loading leads to an abundant display of viral- or 
tumor-derived peptides on the surface of target cells and 
may not reflect the biological situation of viral infections or 
of tumor cells presenting small numbers of altered peptides. 
To overcome these shortcomings, we obtained the A*0201 
positive human lung fibroblast cell line MRC-5. AD169-
infected MRC-5 cells were stained with the ETA′-coupled 
C1 TCR-like antibody. In contrast to primary fibroblasts, 
staining of HCMV-infected MRC-5 cells with the immuno-
toxin C1-ETA′ was possible without prior tetramerization. 
To determine the amount of HCMV-peptide presented on 
the surface of HCMV-infected MRC-5 cells we performed 
HCMV-peptide titration experiments and found comparable 
staining intensities for MRC-5 cells loaded with 10–20 µg/
ml HCMV-peptide as for HCMV-infected MRC-5 cells. 
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When incubated with MRC-5 cells that were loaded with 
12.5 µg/ml HCMV-peptide, C1-ETA′ still was able to exert 
cytotoxic effects, demonstrating its ability to be effective 
even when the target peptide is presented in low concentra-
tions as is the case in HCMV-infection. While very intrigu-
ing, the experimental set-up using peptide-loaded cells is 
still rather artificial and further studies are underway to pro-
vide cytotoxicity data of the A6-, C7- and C1-ETA′ immu-
notoxins on HCMV-infected cells.
It can only be speculated about the best format, HCMV-
specific, TCR-like antibodies could be applied as. The IgG 
antibody format has well defined pharmacokinetics and 
pharmacodynamics but is dependent on cellular toxicity 
in  situations where the cellular immune system is sup-
pressed. This could be overcome by incorporating the iden-
tified TCR-like Fabs into immunotoxins. With the advent of 
chimeric antigen receptor (CAR) T cells, another very pow-
erful treatment option for antibodies becomes available [42].
Future studies should focus on extending our approach 
of a TCR-like antibody repertoire to additional diseases 
like cancers, which seems particularly promising since the 
recent discovery of tumor-specific peptides in CLL, AML 
and CML [43–45].
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